Studien zu Weichteilsarkomen und Knochentumoren in Deutschland
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
https://link.springer.com/content/pdf/10.1007/s00761-022-01110-1.pdf
Reference9 articles.
1. Schmoll HJ, Lindner LH, Reichardt P et al (2021) Efficacy of Pazopanib with or without gemcitabine in patients with anthracycline- and/or Ifosfamide-refractory soft tissue sarcoma: final results of the PAPAGEMO phase 2 randomized clinical trial. JAMA Oncol 7(2):255–262
2. Karch A, Koch A, Grünwald V (2016) A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. Trials 17(1):312
3. Grunwald V, Karch A, Schuler M et al (2020) Randomized comparison of pazopanib and doxorubicin as first-line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German intergroup study. J Clin Oncol 38(30):3555–3564
4. Hartmann JT, Kopp HG, Gruenwald V et al (2020) Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. Eur J Cancer 124:152–160
5. Joensuu H, Eriksson M, Sundby Hall K et al (2020) Survival outcomes associated with 3 years vs 1 year of adjuvant Imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up. JAMA Oncol 6(8):1241–1246
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3